Generic Actos Launched by Mylan, Teva and Ranbaxy

Mylan, Teva and Ranbaxy announced on Friday that they have each launched generic forms of Takeda’s blockbuster type 2 diabetes drug Actos in the US. The generic drugmakers are sharing 180-day exclusivity for the generic versions of the branded medication, which receives in sales of roughly $2.7 billion a year across America. Actos (pioglitazone) is

Continue Reading

Mylan To Generate 500 New Jobs In Ireland

Last week US generics company, Mylan, announced that they will be investing €76 million into expanding their operations in Ireland, in a move that will create 500 new pharmaceutical jobs. By 2016, Mylan expect to have generated roughly 220 jobs in Galway, while 280 will be created at the company’s facilities in Dublin.  The business

Continue Reading